On February 18, 2020 Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), reported that the Company will be participating in two upcoming international conferences (Press release, Onconova, FEB 18, 2020, View Source [SID1234554434]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

1. RAS-Targeted Drug Discovery Summit/Europe
February 25-27
Vienna, Austria

Presentation Details:

Title: Rigosertib is a Unique Small Molecule RAS Antagonist: Scientific & Clinical Studies
Date/Time: Thursday, February 27th, 9:00 AM Central European Time
Venue: Hilton Vienna Plaza
Presenter: Steven M. Fruchtman, M.D., President & CEO of Onconova

About RAS and Rigosertib:

There is a high frequency of RAS mutations in cancer that leads to the belief that mutations of the RAS Pathway provide a proliferative advantage and thus are involved in the pathogenesis of cancer. As a result, targeting the RAS pathway has been the objective of scientific research for decades. As published in the journal Cell in 2016, and now under investigation in a pivotal Phase 3 Trial, rigosertib targets the mutated RAS pathway by its interaction with RAS effector proteins containing the RAS Binding Domain. The RAS-Targeted Drug Discovery Summit provides an opportunity to showcase the potential for rigosertib in MDS and in other RAS-driven cancers, such as KRAS-mutated lung cancer and colorectal cancer, and RAS-driven pediatric cancers as well. Onconova will review its INSPIRE Trial for which the Company anticipates reporting top-line data for second-line, higher-risk MDS patients in the first half of this year, following full enrollment and 288 death events. Dr. Fruchtman looks forward to joining colleagues at the Summit to discuss advancements in rigosertib’s development as well as the progress the Company and others have made in targeting RAS.

2. 2nd Regional Symposium on MDS
March 5-6
Tel Aviv, Israel

"We are pleased to participate in the MDS Conference in Tel Aviv where experts from around the globe will be presenting new data on the diagnosis and management of MDS," said Dr. Steven Fruchtman.